Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Miltefosine plus allopurinol versus miltefosine alone in cutaneous leishmaniasis
IRCT20210823052264N14Phase 3Completed
- Sponsor
- Combined Military Hospital Quetta
- Start
- Jan 2025
- Modality
- Classical Binding Small Molecules → Small Molecules, Covalent Small Molecules → Small Molecules, Nucleic Acid-Directed Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 3 trial of miltefosine and allopurinol in cutaneous leishmaniasis (CL) (2 arms), sponsored by Combined Military Hospital Quetta. Primary endpoint: Clinical Response. Started Jan 2025; status: completed.
02
Drugs
miltefosineallopurinol
03
Conditions
cutaneous leishmaniasis (CL)
Beyond the preview
Go deeper on IRCT20210823052264N14.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on IRCT20210823052264N14.